Frontiers in Immunology (Jan 2023)

Acute and long-term immune responses to SARS-CoV-2 infection in unvaccinated children and young adults with inborn errors of immunity

  • Ana García-García,
  • Ana García-García,
  • Ana García-García,
  • Ana García-García,
  • Claudia Fortuny,
  • Claudia Fortuny,
  • Claudia Fortuny,
  • Claudia Fortuny,
  • Claudia Fortuny,
  • Victoria Fumadó,
  • Victoria Fumadó,
  • Victoria Fumadó,
  • Victoria Fumadó,
  • Victoria Fumadó,
  • Iolanda Jordan,
  • Iolanda Jordan,
  • Iolanda Jordan,
  • Iolanda Jordan,
  • Laura Ruiz-López,
  • Laura Ruiz-López,
  • Europa Azucena González-Navarro,
  • Natalia Egri,
  • Ana Esteve-Solé,
  • Ana Esteve-Solé,
  • Ana Esteve-Solé,
  • Yiyi Luo,
  • Yiyi Luo,
  • Yiyi Luo,
  • Alexandru Vlagea,
  • Alexandru Vlagea,
  • Manel Monsonís Cabedo,
  • Cristian Launes,
  • Cristian Launes,
  • Cristian Launes,
  • Aleix Soler,
  • Anna Codina,
  • Anna Codina,
  • Manel Juan,
  • Manel Juan,
  • Manel Juan,
  • Mariona Pascal,
  • Mariona Pascal,
  • Mariona Pascal,
  • Angela Deyà-Martínez,
  • Angela Deyà-Martínez,
  • Angela Deyà-Martínez,
  • Angela Deyà-Martínez,
  • Laia Alsina,
  • Laia Alsina,
  • Laia Alsina,
  • Laia Alsina,
  • Laia Alsina

DOI
https://doi.org/10.3389/fimmu.2023.1084630
Journal volume & issue
Vol. 14

Abstract

Read online

PurposeTo describe SARS-CoV-2 infection outcome in unvaccinated children and young adults with inborn errors of immunity (IEI) and to compare their specific acute and long-term immune responses with a sex-, age-, and severity-matched healthy population (HC).MethodsUnvaccinated IEI patients up to 22 years old infected with SARS-CoV-2 were recruited along with a cohort of HC. SARS-CoV-2 serology and ELISpot were performed in the acute phase of infection (up to 6 weeks) and at 3, 6, 9, and 12 months.ResultsTwenty-five IEI patients (median age 14.3 years, min.-max. range 4.5-22.8; 15/25 males; syndromic combined immunodeficiencies: 48.0%, antibody deficiencies: 16.0%) and 17 HC (median age 15.3 years, min.-max. range 5.4-20.0; 6/17 males, 35.3%) were included. Pneumonia occurred in 4/25 IEI patients. In the acute phase SARS-CoV-2 specific immunoglobulins were positive in all HC but in only half of IEI in whom it could be measured (n=17/25): IgG+ 58.8% (10/17) (p=0.009); IgM+ 41.2% (7/17)(p<0.001); IgA+ 52.9% (9/17)(p=0.003). Quantitative response (index) was also lower compared with HC: IgG IEI (3.1 ± 4.4) vs. HC (3.5 ± 1.5)(p=0.06); IgM IEI (1.9 ± 2.4) vs. HC (3.9 ± 2.4)(p=0.007); IgA IEI (3.3 ± 4.7) vs. HC (4.6 ± 2.5)(p=0.04). ELISpots positivity was qualitatively lower in IEI vs. HC (S-ELISpot IEI: 3/11, 27.3% vs. HC: 10/11, 90.9%; p=0.008; N-ELISpot IEI: 3/9, 33.3% vs. HC: 11/11, 100%; p=0.002) and also quantitatively lower (S-ELISpot IEI: mean index 3.2 ± 5.0 vs. HC 21.2 ± 17.0; p=0.001; N-ELISpot IEI: mean index 9.3 ± 16.6 vs. HC: 39.1 ± 23.7; p=0.004). As for long term response, SARS-CoV-2-IgM+ at 6 months was qualitatively lower in IEI(3/8, 37.5% vs. 9/10 HC: 90.0%; p=0.043), and quantitatively lower in all serologies IgG, M, and A (IEI n=9, 1.1 ± 0.9 vs. HC n=10, 2.1 ± 0.9, p=0.03; IEI n=9, 1.3 ± 1.5 vs. HC n=10, 2.9 ± 2.8, p=0.02; and IEI n=9, 0.6 ± 0.5 vs. HC n=10, 1.7 ± 0.8, p=0.002 –respectively) but there were no differences at remaining time points.ConclusionsOur IEI pediatric cohort had a higher COVID-19 pneumonia rate than the general age-range population, with lower humoral and cellular responses in the acute phase (even lower compared to the reported IEI serological response after SARS-CoV-2 vaccination), and weaker humoral responses at 6 months after infection compared with HC.

Keywords